NASDAQ:AMEDAmedisys Stock Price, Forecast & News

Amedisys' stock was trading at $170.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMED stock has increased by 12.6% and is now trading at $191.89. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amedisys.

Amedisys is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Amedisys.

Amedisys Inc (NASDAQ:AMED) posted its quarterly earnings results on Tuesday, February, 18th. The health services provider reported $0.94 EPS for the quarter, topping the consensus estimate of $0.93 by $0.01. The health services provider earned $500.70 million during the quarter, compared to analysts' expectations of $511.58 million. Amedisys had a return on equity of 24.95% and a net margin of 6.49%. The business's revenue was up 15.3% compared to the same quarter last year. During the same period last year, the company posted $0.91 earnings per share. View Amedisys' earnings history.

Amedisys updated its FY20 earnings guidance on Tuesday, February, 18th. The company provided earnings per share (EPS) guidance of $4.90-5.13 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.91. The company issued revenue guidance of $2.115-2.160 billion, compared to the consensus revenue estimate of $2.12 billion.

13 brokerages have issued 12-month price objectives for Amedisys' stock. Their forecasts range from $125.00 to $225.00. On average, they expect Amedisys' stock price to reach $182.86 in the next twelve months. This suggests that the stock has a possible downside of 4.7%. View analysts' price targets for Amedisys.

News coverage about AMED stock has been trending very negative recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amedisys earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the health services provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAmedisys.

Amedisys saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,117,200 shares, an increase of 6.4% from the February 27th total of 1,050,000 shares. Based on an average daily trading volume, of 292,900 shares, the short-interest ratio is currently 3.8 days. Currently, 3.5% of the company's stock are sold short. View Amedisys' Current Options Chain.

Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), NVIDIA (NVDA), Cisco Systems (CSCO), CVS Health (CVS), Micron Technology (MU), Netflix (NFLX), Verizon Communications (VZ), Adobe (ADBE), QUALCOMM (QCOM) and Pfizer (PFE).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by many different institutional and retail investors. Top institutional investors include Gradient Investments LLC (0.07%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps. View institutional ownership trends for Amedisys.

AMED stock was acquired by a variety of institutional investors in the last quarter, including Gradient Investments LLC, and State of Alaska Department of Revenue. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps. View insider buying and selling activity for Amedisys.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMED stock can currently be purchased for approximately $191.89.

Amedisys has a market capitalization of $6.20 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe. View additional information about Amedisys.

The official website for Amedisys is http://www.amedisys.com/.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]